KALARIS THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
KALARIS THERAPEUTICS, INC. (KLRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 396.15 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 379.01K shares.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 17.14K shares.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was -4.18M shares, a 7883.35% decline year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 446.71K shares, a 135.80% increase year-over-year.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 211.13K shares, a 10.48% increase from fiscal 2024.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 191.11K shares, a 84.86% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.26M shares, a 1.70% decline from fiscal 2022.
- KALARIS THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.28M shares, a 372.83% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 379.01K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 396.15K shares 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | 17.14K shares 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 211.13K shares 10-K · filed 2026-03-17 | |||
| 2024-12-31 | -4.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -3.73M shares derived: sum of 2 quarters · filed 2025-03-07 | -1.65M shares derived: sum of 3 quarters · filed 2025-03-07 | 191.11K shares 10-K · filed 2025-03-07 |
| 2024-09-30 | 446.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 2.52M shares derived: sum of 2 quarters · filed 2024-11-12 | 4.37M shares 10-Q · filed 2024-11-12 | 4.42M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 2.08M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 3.92M shares 10-Q · filed 2024-08-09 | 3.97M shares derived: sum of 3 quarters · filed 2024-08-09 | 4.16M shares derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | 1.85M shares 10-Q · filed 2024-05-13 | 1.90M shares derived: sum of 2 quarters · filed 2024-05-13 | 2.09M shares derived: sum of 3 quarters · filed 2024-05-13 | 2.58M shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 53.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | 243.10K shares derived: sum of 2 quarters · filed 2024-03-15 | 734.62K shares derived: sum of 3 quarters · filed 2024-03-15 | 1.26M shares 10-K · filed 2024-03-15 |
| 2023-09-30 | 189.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 680.96K shares derived: sum of 2 quarters · filed 2023-11-02 | 1.21M shares 10-Q · filed 2023-11-02 | 1.86M shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 491.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 1.02M shares 10-Q · filed 2023-08-03 | 1.67M shares derived: sum of 3 quarters · filed 2023-08-03 | 1.78M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 527.77K shares 10-Q · filed 2023-05-04 | 1.18M shares derived: sum of 2 quarters · filed 2023-05-04 | 1.29M shares derived: sum of 3 quarters · filed 2023-05-04 | 1.40M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 654.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | 760.74K shares derived: sum of 2 quarters · filed 2023-02-15 | 872.23K shares derived: sum of 3 quarters · filed 2023-02-15 | 1.28M shares 10-K · filed 2023-02-15 |
| 2022-09-30 | 106.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 218.09K shares derived: sum of 2 quarters · filed 2022-11-03 | 630.03K shares 10-Q · filed 2022-11-03 | 702.47K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 111.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 523.43K shares 10-Q · filed 2022-08-04 | 595.87K shares derived: sum of 3 quarters · filed 2022-08-04 | 760.79K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 411.94K shares 10-Q · filed 2022-05-05 | 484.38K shares derived: sum of 2 quarters · filed 2022-05-05 | 649.30K shares derived: sum of 3 quarters · filed 2022-05-05 | 669.53K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 72.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | 237.37K shares derived: sum of 2 quarters · filed 2022-02-10 | 257.59K shares derived: sum of 3 quarters · filed 2022-02-10 | 271.59K shares 10-K · filed 2022-02-10 |
| 2021-09-30 | 164.92K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | 185.15K shares derived: sum of 2 quarters · filed 2021-11-05 | 199.15K shares 10-Q · filed 2021-11-05 | |
| 2021-06-30 | 20.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | 34.23K shares 10-Q · filed 2021-08-06 | ||
| 2021-03-31 | 14.00K shares 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | 25.00K shares 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |